Recent advances in next‐generation sequencing (NGS) have shed light on genomic alterations underlying breast cancer subtypes and paved the way for successful development of targeted therapies such as PIQRAY® (alpelisib) for certain PIK3CA mutations [2]. Here, PIK3CA is linked to breast carcinoma.